Friday, Jan 23, 2026 · SEC filings

What the smart money revealed on Jan 23

Real insider buys22insiders · $10.7M
Real insider sales43insiders · $54.8M
Fund 13Fs filed—not loaded for this day
Activist 13Ds filed—not loaded for this day

487 insider filings came in. We hid 55 planned (10b5-1) sellers and 357 people whose filings were routine, like grants and tax withholding.

group

3 insiders at Keystone Private Income Fund bought $4M of stock

Roles: President, Treasurer, Director. Several insiders buying in the same few days is rare.

Cluster buy Form 4 Traded Jan 1
$4M
trending_up

Blackstone Real Estate Income Trust (BSTT) Co-President A.J. Agarwal bought $4M

287,319 shares on the open market. Not a grant or an option exercise.

Real buy Form 4 Traded Dec 1
$4M
trending_up

TCG Strategic Income Fund (TCGSX) Director Leonard Tannenbaum bought $1M

98,912 shares on the open market. Not a grant or an option exercise. Their past buys: 2 of 11 checked quarters beat the typical stock 6 months later.

Real buy Form 4 Past buys: 2 of 11 beat Traded Jan 21
$1M
trending_up

Ally Financial (ALLY) CEO Michael Rhodes bought $992K

23,800 shares on the open market. Not a grant or an option exercise.

Real buy Form 4 Traded Jan 23
$992K
trending_up

RLI (RLI) CEO Craig Kliethermes bought $287K

5,000 shares on the open market. Not a grant or an option exercise.

Real buy Form 4 Traded Jan 23
$287K
trending_down

BlackRock (BLK) Senior Managing Director J. Kushel sold $22.5M

Not marked as a planned 10b5-1 sale. Sold 24% of the shares they held directly. Still holds 61,894 shares.

Real sale Form 4 Traded Jan 21
$22.5M
trending_down

Argan (AGX) Director Cynthia Flanders sold $7.35M

Not marked as a planned 10b5-1 sale. Sold 42% of the shares they held directly. Still holds 26,207 shares.

Real sale Form 4 Sold 42% of stake Traded Jan 21
$7.35M
trending_down

M&T Bank (MTB) Director John Barnes sold $3.94M

Not marked as a planned 10b5-1 sale. Sold every share held directly.

Real sale Form 4 Sold 100% of stake Traded Jan 22
$3.94M
Show 15 more real buys
Show 40 more real sales
AMPX Amprius Technologies · CTO Constantin Stefan · Traded Jan 21–23
$6.83M
DC Dakota Gold · CEO Robert Quartermain · Traded Jan 23
$1.72M
CAVA Cava Group · CEO and President Brett Schulman · Traded Jan 21
$1.46M
PL Planet Labs PBC · Director Kristen Robinson · Traded Jan 21
$1.29M
CMA Comerica · Executive Vice Pres. James Carr · Traded Jan 22
$981K
CMA Comerica · Executive Vice President James Weber · Traded Jan 22
$863K
COST Costco Wholesale · Executive Vice President Teresa Jones · Traded Jan 21
$838K
JBHT J.B. Hunt Transport Services · President of DCS Bradley Hicks · Traded Jan 22
$823K
KEY KeyCorp · Director Trina Evans · Traded Jan 22
$711K
MIRM Mirum Pharmaceuticals · CEO Christopher Peetz · Traded Jan 22
$662K
APLS Apellis Pharmaceuticals · CEO Cedric Francois · Traded Jan 22
$592K
PL Planet Labs PBC · Director Vijaya Gadde · Traded Jan 22
$535K
AIR AAR · VP-CAO & Controller Eric Pachapa · Traded Jan 22
$528K
UCB United Community Banks · SVP Alan Kumler · Traded Jan 23
$426K
DC Dakota Gold · CFO Shawn Campbell · Traded Jan 21
$346K
JBHT J.B. Hunt Transport Services · EVP Safety Ronald Woodruff · Traded Jan 21
$288K
APLS Apellis Pharmaceuticals · CFO Timothy Sullivan · Traded Jan 22
$224K
MIRM Mirum Pharmaceuticals · President and COO Peter Radovich · Traded Jan 22
$222K
APLS Apellis Pharmaceuticals · General Counsel David Watson · Traded Jan 22
$171K
MIRM Mirum Pharmaceuticals · Chief Medical Officer Joanne Quan · Traded Jan 22
$170K
APLS Apellis Pharmaceuticals · Chief Technical Officer Nur Nicholson · Traded Jan 22
$168K
CAVA Cava Group · CFO Tricia Tolivar · Traded Jan 21
$149K
MIRM Mirum Pharmaceuticals · CFO Eric Bjerkholt · Traded Jan 22
$133K
APLS Apellis Pharmaceuticals · Chief Scientific Officer Pascal Deschatelets · Traded Jan 22
$129K
CAVA Cava Group · Chief People Officer Kelly Costanza · Traded Jan 21
$115K
MIRM Mirum Pharmaceuticals · SVP Jolanda Howe · Traded Jan 22
$86.4K
APLS Apellis Pharmaceuticals · Chief Business & Strat Officer Mark DeLong · Traded Jan 22
$73.4K
CAVA Cava Group · CLO & Secretary Kenneth Bertram · Traded Jan 21
$72.4K
CAVA Cava Group · Chief Concept Officer Theodoros Xenohristos · Traded Jan 21
$65.1K
APLS Apellis Pharmaceuticals · Chief Medical Officer Caroline Baumal · Traded Jan 22
$60.9K
IMVT Immunovant · CTO Jay Stout · Traded Jan 21
$51.5K
AEO American Eagle Outfitters · Director Noel Spiegel · Traded Jan 21
$48.7K
APLS Apellis Pharmaceuticals · VP/Chief Accounting Officer James Chopas · Traded Jan 22
$44.9K
ALLO Allogene Therapeutics · EVP of R&D Zachary Roberts · Traded Jan 21
$41K
ABOS Acumen Pharmaceuticals · CEO Daniel OConnell · Traded Jan 21–22
$22K
ABOS Acumen Pharmaceuticals · Chief Legal Officer & Corp Sec Derek Meisner · Traded Jan 21–23
$16.7K
ABOS Acumen Pharmaceuticals · CFO & Chief Business Officer Matt Zuga · Traded Jan 21–22
$7.61K
ABOS Acumen Pharmaceuticals · Chief Medical Officer Eric Siemers · Traded Jan 21–22
$5.82K
PLNH Planet 13 · VP of Operations Chris Wren · Traded Jan 23
$5.7K
ABOS Acumen Pharmaceuticals · COO Russell Barton · Traded Jan 21–22
$5.04K

13F season

Holdings as of Dec 31, 2025 are due Feb 17

320 funds have filed so far. 81 filed for the quarter before.

Biggest real insider buys this week

Open-market buys by officers and directors, filed in the 7 days up to Jan 23.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist